Lexeo Therapeutics, Inc. - Common Stock (LXEO)

97 filings reported holding LXEO - Lexeo Therapeutics, Inc. - Common Stock as of Q4 2024.
Lexeo Therapeutics, Inc. - Common Stock (LXEO) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 29,519,159 shares of 72,987,327 outstanding shares and own 40% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (4,339,254 shares), CITADEL ADVISORS LLC (2,723,363 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2,209,615 shares), D1 Capital Partners L.P. (2,203,900 shares), BlackRock, Inc. (1,821,966 shares), EVENTIDE ASSET MANAGEMENT, LLC (1,234,834 shares), Vestal Point Capital, LP (1,200,000 shares), Omega Fund Management, LLC (1,184,636 shares), Blackstone Inc. (1,158,617 shares), and Novo Holdings A/S (1,122,581 shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.